---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030123"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:17:47.807736+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing

## Summary
- Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.
- Revenue $10.8M (vs <$0.1M YoY) driven by $7.5M TG Therapeutics milestone payment for Azer-Cel.
- Cash, equivalents, restricted cash $125.8M as of March 31; expected funding through 2028.
- PBGENE-HBV: 16 patients treated across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30.
- PBGENE-DMD: FDA IND clearance, Fast Track; first site (Arkansas Children's Hospital) activated, enrolling patients.

## SEC filing metadata
- accession: 0001628280-26-030123
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/0001628280-26-030123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/dtil-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030123
- JSON: https://secwatch.observer/filing/0001628280-26-030123.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030123.txt

## Source-grounded claims
- claim_id: d9057e6d4e3b09cbe417f2e71a94c99475804842
  claim: PRECISION BIOSCIENCES INC reported financial results for first quarter ended March 31, 2026.
  evidence_excerpt: Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/0001628280-26-030123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.